Sugi Predict

Sugi Predict / Compounds / SCHEMBL372142

SCHEMBL372142

SCHEMBL372142

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)O)CC4)cc3)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 4/20 1.00
▸ FLT3 P36888 2/20 1.00
▸ AXL P30530 10/20 0.82
▸ MET P08581 10/20 0.82
▸ KDR P35968 5/20 0.82
▸ FLT1 P17948 3/20 0.82
▸ MERTK Q12866 3/20 0.82
▸ AURKA O14965 1/20 0.82
▸ RIPK2 O43353 1/20 0.82
▸ ABCB11 O95342 1/20 0.82
▸ ABL1 P00519 1/20 0.82
▸ EGFR P00533 1/20 0.82
▸ ERBB2 P04626 1/20 0.82
▸ NTRK1 P04629 1/20 0.82
▸ LCK P06239 1/20 0.82
▸ PGR P06401 1/20 0.82
▸ LYN P07948 1/20 0.82
▸ RET P07949 1/20 0.82
▸ CHRM2 P08172 1/20 0.82
▸ HCK P08631 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18676441 0.95 AURKB (0.91) AURKBFLT3AXLMETKDR
SCHEMBL30918289 0.95 AXL (0.90) AURKBFLT3AXLMETKDR
SCHEMBL15872120 0.95 AXL (0.90) AURKBFLT3AXLMETKDR
SCHEMBL20952840 0.94 AURKB (0.89) AURKBFLT3AXLMETKDR
SCHEMBL18676548 0.94 AURKB (0.88) AURKBFLT3AXLMETKDR
SCHEMBL16083191 0.93 AURKB (0.87) AURKBFLT3AXLMETKDR
SCHEMBL16069957 0.93 AURKB (0.87) AURKBFLT3AXLMETKDR
SCHEMBL371951 0.93 AURKB (0.87) AURKBFLT3AXLMETKDR
SCHEMBL17117767 0.93 AURKB (0.86) AURKBFLT3AXLMETKDR
SCHEMBL16069958 0.93 AURKB (0.86) AURKBFLT3AXLMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658271-A1 IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE Handa Oncology, LLC (US) 2025-12-10 — — EP claimed
WO-2024163400-A1 IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE HANDA ONCOLOGY, LLC (US) 2024-08-08 — — WO claimed
US-20260138953-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE HANDA ONCOLOGY, LLC (US) 2026-05-21 — — US disclosed
US-12552749-B2 Cabozantinib compositions and methods of use HANDA ONCOLOGY, LLC (US) 2026-02-17 — — US disclosed
US-12522567-B2 Cabozantinib compositions and methods of use HANDA ONCOLOGY, LLC (US) 2026-01-13 — — US disclosed
US-12516026-B2 Cabozantinib compositions and methods of use HANDA ONCOLOGY, LLC (US) 2026-01-06 — — US disclosed
US-12516025-B2 Cabozantinib compositions and methods of use HANDA ONCOLOGY, LLC (US) 2026-01-06 — — US disclosed
EP-4658271-A1 IMPROVED CABOZANTINIB COMPOSITIONS AND METHODS OF USE Handa Oncology, LLC (US) 2025-12-10 — — EP disclosed
US-20250340515-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE HANDA ONCOLOGY, LLC (US) 2025-11-06 — — US disclosed
US-12415784-B2 Cabozantinib compositions and methods of use HANDA ONCOLOGY, LLC (US) 2025-09-16 — — US disclosed
US-20250257036-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE HANDA ONCOLOGY, LLC (US) 2025-08-14 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
WO-2006108059-A1 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2006-10-12 — — WO disclosed
EP-1673085-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-06-28 — — EP disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AURKB 790/4885FLT3 7/4885AXL 109/4885
US-12415784-B2 Cabozantinib compositions and methods of use KRAS, GSK3B, KSR2 AURKB 289/4885FLT3 62/4885AXL 91/4885
US-20260138953-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE CTNND1, CSNK1D, SLC34A2 AURKB 1456/4885FLT3 27/4885AXL 377/4885
US-12552749-B2 Cabozantinib compositions and methods of use SI, CCNB1, GYS1 AURKB 60/4885FLT3 347/4885AXL 77/4885
US-20250257036-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE KRAS, GSK3B, KSR2 AURKB 289/4885FLT3 62/4885AXL 91/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 AURKB 559/4885FLT3 7/4885AXL 241/4885
US-20250340515-A1 CABOZANTINIB COMPOSITIONS AND METHODS OF USE KRAS, CYP3A5, CYP3A43 AURKB 525/4885FLT3 63/4885AXL 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.